



Life Sciences
British Columbia

INVEST IN BC

presented by



VENTURES

Pitching Company Guide

November 3 & 4, 2021 | 9AM - 5PM PT

The premier investment pitch days for the
life sciences industry.

Table of Contents

About Us	3
Introduction	4
4M Biotech	5
AltumView Systems Inc.,	5
Axolotl Biosciences	6
Azor Biotek Inc.	6
Bold Therapeutics Inc.	7
Clairvoyant Therapeutics Inc.	7
Claris Healthcare Inc.	8
Derm-Biome Pharmaceuticals, Inc.	8
HeadCheck Health	9
Herstasis Health Inc.	9
HTuO Biosciences	10
Mesentech Inc.	10
Mesintel Therapeutics Inc.	11
Microbiome Insights	11
Microbion Corporation	12
NanoVation Therapeutics	12
NervGen Pharma Corp.	13
Oak Bay Biosciences Inc.	13
Primary Peptides Inc.	14
RepliCel Life Sciences	14

Rostrum Medical Innovations	15
SaNOTize	15
Sonic Incytes Medical Corp.	16
Sustained Therapeutics Inc.	16
Total Flow Medical	17
Variational AI	17
Vesalius Cardiovascular	18
VoxCell BioInnovation	18
XCO Tech Inc.	19
YouCount Inc.	19
Zennea Technologies Inc.	20



Life Sciences BC has over 250 member organizations from within our vibrant BC life sciences community. This booklet features the companies attending Invest in BC presented by Lumira Ventures.

For a full list of our members please see [our website](#).



About Us

Life Sciences British Columbia is a not-for-profit, non-government industry association that supports and represents the life sciences community of B.C. through numerous initiatives at the local, national and international level. We nurture economic development in the province through leadership; facilitation of investment and partnering; advocacy; and promotion of our world-class life sciences industry.



Wendy Hurlburt

President & CEO, Life Sciences BC

I am thrilled to present the 2021 life sciences companies pitching at the sixth annual Life Sciences BC Invest in BC conference, presented by Lumira Ventures. Our BC life sciences sector comprises a broad range of companies—from small and emerging to national and global—all with a need for strong and strategic investment and partnerships. Invest in BC provides an opportunity to secure investment and new partnerships as companies continue to advance their life science innovation products, solutions, and services.



Welcome Remarks

Welcome to our sixth annual Invest in BC, presented by Lumira Ventures. We're delighted to present a broad range of investor-ready BC life sciences companies to more than 350 attendees gathered from 31 countries on six continents.

Please take a virtual seat as our entrepreneurs tell their stories, pitching to angel investors, venture capitalists, government investment and trade officials, and representatives from corporate ventures teams and funding foundations. You will hear from companies in therapeutics, medical devices, and digital health among others.

Invest in BC is one of LSBC's investment- and innovation-focused signature events. Throughout the year, we raise the life sciences profile at home and abroad to encourage investment and global partnering opportunities.

At Invest in BC, not only are we providing opportunities for both the SME and investor, but we also highlight the amazing life sciences opportunities in our province.

BC is open for business, and none more so than our life sciences sector. We're the third largest life sciences sector in Canada and the fastest growing, with strong provincial support that recognizes the value of investment for local and global impact. We're a strong and sustainable sector, ready to contribute to provincial growth. Over the past year and more, BC life sciences has kept growing; during 2020, capital raising rose to \$2.3 billion CAD, an increase of 123 per cent.

Life Sciences BC would like to wish success to all those taking part. Thank you to all our event sponsors—including Lumira Ventures, our presenting sponsor, and conference partner, adMare Bioinnovations—we're grateful for your continued support.



4M Biotech



4M BioTech is a Victoria-based biotechnology company that specializes in developing advanced sensing and IoMT technology. Founded in 2018 as a University of Victoria spin-off, 4M BioTech's multidisciplinary team utilizes their collective expertise in cellular biology, biomaterials, engineering, and artificial intelligence to create innovative solutions for infection prevention and management. The company's flagship product is the GelDerm Smart Dressing – an infection sensing wound dressing that changes colour in response to infection.



AltumView Systems Inc.



AltumView is an AI company in Vancouver. It has developed two generations of Sentinare smart activity sensor for senior care and remote patient monitoring, which was a CES 2021 Innovation Awards Honoree. The sensor has a build-in AI chip, and uses the latest deep learning algorithms to monitor the activities of people, collect useful health statistics, and notify the caregivers immediately when emergencies such as falls are detected. To protect the privacy, only stick figure animations are transmitted, instead of raw videos. The system is especially useful in the wake of the COVID-19 pandemic.



Axolotl Biosciences



Axolotl Biosciences - a Victoria based biotechnology company, provides innovative products for 3D bioprinting as a way to advance the field of regenerative medicine. Their short-term strategy focuses on production and distribution of their novel bioinks as reagents for use by academic researchers while generating revenue starting this year. Strong demand for their bioinks exists from academic researchers due to their superior performance compared to commercially available bioinks, giving them a competitive advantage for capturing a significant share of the \$400 million market for these products.



Azor Biotek Inc.



Azor Biotek is a privately held Canadian pharmaceutical design and development corporation based in Victoria BC. They have developed an RNA-compatible software suite for structure-guided design of small molecule drugs. Their NRC-IRAP funded pilot study is investigating small molecules designed to target and counteract pathologically underexpressed microRNA to treat Parkinson's disease and post-COVID pulmonary fibrosis. Their drug design methods will be equally applicable to many other disease states with unmet treatment needs. Their development pipeline is outsourced through Canadian collaborators, and patented therapeutics will be out-licensed following phase I clinical trials.



Bold Therapeutics Inc.



Bold Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing novel oncology therapeutics. Its lead product, BOLD-100, is a first-in-class, clinical-stage, small molecule that targets both acquired and intrinsic cancer drug resistance. By defeating cancer drug resistance, BOLD-100 has the potential to significantly improve outcomes in a range of patients, including some of the most difficult-to-treat cancers. BOLD-100 has shown activity across a large range of both solid and liquid cancers and in combination with virtually all other anti-cancer therapies. The company is raising a USD\$20M Series B to complete its current Phase 2 clinical study and initiate additional studies.



Clairvoyant Therapeutics Inc.



Clairvoyant Therapeutics is a Canadian biotech company focused on psychedelic therapy drug development for addiction. Clairvoyant is at the forefront of a growing psychedelic therapy industry and operates under the principles of open science. Clairvoyant is launching a phase 2 psilocybin therapy for alcohol use disorder in 2021 with up to 15 clinical sites in Canada and the EU. Their team has a successful track record of designing and operating clinical trials and bringing new drugs to market.



Clariss Healthcare Inc.



Clariss Healthcare was founded in 2012 to develop technology to support the transition of care out of institutional settings into the home. They have developed an engaging, accessible and reliable health care platform for the delivery of care, particularly for older patients. The Clariss platform can deliver any type of care, addressing issues from social isolation through remote patient monitoring and telehealth for chronic conditions to coaching patients through acute interventions. The advent of the COVID-19 pandemic has emphasized the need for this transition and has made it a matter of urgency.



Derm-Biome Pharmaceuticals Inc.



Derm-Biome Pharmaceuticals, Inc. is a preclinical biopharmaceutical company from Vancouver, Canada focused on developing safe and effective topical therapies for those suffering from debilitating skin ailments. They recently developed a new generation of natural product-based derivatives that show significant promise to be future standards of care for chronic inflammatory skin diseases such as atopic dermatitis and psoriasis, as well as skin cancers.



HeadCheck Health



HeadCheck Health is a digital health venture providing concussion management and risk mitigation technologies to sports organizations. As the only feasible solution available in the market, HeadCheck aims to be the de facto standard platform for all sports organizations to execute and monitor concussion protocols. Over 3,000 paid sports teams currently mandate HeadCheck's platform, from full mainstream professional leagues such as Major League Soccer to grassroots youth sports organizations throughout North America. The company is entering an inflection period in the large North American concussion-risk sports market (5M teams, \$3.8B ARR).



Herstasis Health Inc.



Herstasis Health is a Vancouver-based life sciences company delivering personalized symptom management tools and translated scientific knowledge to 200 million women aged 35-55 experiencing a difficult perimenopausal transition.



HTuO Biosciences



HTuO Biosciences is on a mission to make the process of designing drugs faster and more efficient, and to make it possible to target proteins that are currently outside the scope of traditional drug design - all while making it cheaper to bring those drugs to market. They believe that the best way to improve their understanding of molecular interactions is to create more accurate models, both of the molecules of interest as well as the solvent in which they're interacting. By using high-accuracy atomic models, they can better predict how molecules will behave, and therefore better predict how drugs interact with their intended targets.



Mesentech Inc.



Mesentech selectively delivers prostaglandin (a crucial signaling hormone triggering regeneration) to specific tissues. Only a small percentage of parenterally administered drugs reach bone; therefore, a higher dose is required. The resulting high serum levels cause side-effects that preclude these pharmaceuticals from clinical use. Mesentech has developed a molecular carrier that selectively delivers the pharmacological payload to bone-tissue. This eliminates the peripheral organ exposure while maintaining pharmacological efficacy. Founder Dr. Robert Young is a medicinal chemist with exceptional track record leading the teams that discovered SingulAir, Arcoxia, among others, with cumulative revenue exceeding \$100B.




Mesintel Therapeutics Inc.



Mesintel has developed a proprietary target discovery platform that incorporates their extensive knowledge of mesenchymal progenitor (MP) biology, coupled with disease-specific datasets mined by state-of-the-art AI/ML capabilities. The platform is designed to accelerate the development of therapeutics centered around the key role MPs play in driving disease, including rare oncology and the solid tumor microenvironment. These efforts will enable Mesintel to leverage its platform into complementary therapeutic areas, such as rare disease, fibrosis, tissue regeneration and aging. They are seeking opportunities to propel collaborative discovery and development partnerships, and seed funding to advance internal programs and platform capabilities.

Microbiome Insights



Microbiome Insights, Inc. is a global leader providing end-to-end microbiome sequencing and comprehensive bioinformatic analysis. The company is headquartered in Vancouver, Canada where samples from around the world are processed in its College of American Pathologist (CAP) accredited laboratory. Working with clients from pharma, biotech, nutrition, cosmetic and agriculture companies as well as with world leading academic and government research institutions, MBI has supported over 600 microbiome studies from basic research to commercial R&D and clinical trials. The company's team of expert bioinformaticians and data scientists deliver industry leading insights including biomarker discovery, machine-learning based modelling and customized bioinformatics analysis.



Microbion Corporation



Microbion is a clinical-stage pharmaceutical company developing pravibismane, the first drug in a new class with a novel mechanism of action that facilitates broad-spectrum potency against multidrug-resistant bacterial pathogens and an unprecedented ability to prevent and eradicate bacterial biofilms. Inhaled pravibismane is in development for treatment of nontuberculous mycobacteria and cystic fibrosis lung infections, with Ph.1 studies anticipated to begin in 2022. Topical pravibismane is in Ph. 2 development for treatment of chronic wounds. Safe and well-tolerated in over 325 humans across five clinical trials, pravibismane's potential has been validated through \$28M in non-dilutive grants awarded from CARB-X, Cystic Fibrosis Foundation, NIH, U.S. DoD, and Navy/MTEC.



NanoVation Therapeutics



NanoVation Therapeutics (NTx) is an early-stage gene therapy company developing next-generation platform technologies utilizing lipid nanoparticles for the safe and efficient delivery of nucleic acids to a variety of tissues. Focused on translating personalized gene therapies to the clinic, NTx aims to treat and prevent multiple age-related diseases enabling a healthier tomorrow, TODAY.



NervGen Pharma Corp.



NervGen is a clinical stage biotech company developing novel treatments for CNS damage. The company's lead product NVG-291 targets a class of molecules that inhibit CNS repair called CSPGs via their primary receptor, PTP σ . In animal models NVG-291 has demonstrated multiple repair mechanisms including regeneration, remyelination, and plasticity. Functional benefit crossing the four major neurological functions (motor, sensory, autonomic, and cognitive) have been demonstrated in six different disease models. A Phase 1 trial in healthy subjects is ongoing and NervGen intends to initiate Phase 1b/2a trials in Alzheimer's disease, MS and spinal cord injury patients, in 2022.



Oak Bay BioSciences, Inc.



Founded in 2020, Oak Bay Biosciences is a preclinical stage biotech developing a therapy for Stargardt disease, an inherited condition that affects 1:10,000 people and leads to progressive and irreversible blindness, often beginning in childhood. Oak Bay Bio's lead molecule is an optimized nucleic acid aptamer that inhibits complement factor D, which is a critical regulator of the alternative complement pathway that has been shown to mediate retinal damage in Stargardt disease. The company has established a team of experts, an experienced Board, and key scientific collaborations to complete its preclinical data package ahead of anticipated clinical trials.



Primary Peptides Inc.



Creating New Therapeutics via Protein Manipulation

Primary Peptides Inc. is a clinical-stage biotechnology company focused on creating new peptide therapeutics via protein manipulation, in Cardiovascular Disease (CVD), Oncology and Neurodegeneration. They manipulate proteins using two platform technologies: 1) Protein-protein interference blockade precisely disrupts the interactions of disease-causing proteins; and 2) Chaperone-mediated Autophagy Protein Degradation Technology (CHAPTAC) degrades disease proteins via the lysosome or the proteasome. CHAPTAC is more versatile than PROTAC in cases where the proteasome is dysfunctional. Their three CVD assets (1 clinical and 2 pre-IND) are partnered with Chinese companies for Greater China. Their five earlier stage assets in Oncology and Neurodegeneration are unpartnered.



RepliCel Life Sciences Inc.



RepliCel is a regenerative medicine company focused on developing products for large-market aesthetic and orthopedic conditions. The company's clinical development pipeline includes cell therapies targeting aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. RepliCel's nearest-term commercial product is an electronic, multi-needle dermal injector developed for the highly consistent and precise delivery of injectable solutions into the skin and extracellular matrix supporting it. RepliCel's three cell therapy products have now been tested in over 100 patients in four countries on three continents. RepliCel has strategic partners in the United States, China, and Japan co-investing in clinical testing and development of RepliCel's products for their markets.



Rostrum Medical Innovations



Rostrum Medical is a privately held corporation, registered under the laws of Canada. Rostrum is uniquely positioned to address the \$3Bil mechanical ventilation market. Rostrum's VQm Pulmonary Health Monitor™ is a novel device which provides clinicians physiological insight into the effects of mechanical ventilation on patients' lung mechanics. To date, physicians have had to rely on multiple sources of data acquisition, some requiring invasive arterial blood gas analysis, resulting in time delays for making critical clinical decisions. The VQm Pulmonary Health Monitor™ provides comprehensive diagnostic data, non-invasively, in near real-time, at the patient's bedside.



SaNOtize



SaNOtize developed a proprietary method of delivering Nitric Oxide (NO) topically, at the effective dose, to the site of infection. NO, a naturally occurring molecule, is well-known to have antimicrobial and anti-inflammatory properties. SaNOtize uses a NO-releasing solution or gel delivered through a nasal spray, nasal wash, gargle or other delivery mechanisms. Intellectual property covers the formulation as well as a variety of delivery devices. With SaNOtize's antiviral nasal spray sales commencing in July 2021, the Company has already sold >150,000 nasal sprays, projects ~\$9 million in 2021 revenues, has a rapidly growing sales pipeline and expects profitability in 2022.



Sonic Incytes Medical Corp.



Sonic Incytes believes in creating accessible and affordable diagnostic solutions – with health insights you can count on – to improve patient care. Recognizing the rise of chronic liver disease, Sonic Incytes has made it its mission to reduce the disease by enabling routine assessment and improved management of liver health. Its breakthrough, point of care ultrasound solution, Velacur™, is redefining the standard of care in quantifying chronic liver disease – with diagnostic accuracy comparable to MRI. Founded in 2017, Sonic Incytes is a health technology company headquartered in Vancouver, British Columbia, Canada. Follow them on Twitter, LinkedIn, YouTube and www.sonicincytes.com.



Sustained Therapeutics Inc.



Sustained Therapeutics is a clinical stage (phase II) company with a patent-issued novel IP for a sustained-release drug delivery platform. This technology is being used to deliver localized delivery of approved drugs, serving large unmet medical needs with significant market potential. Its lead product (ST-01) is a formulation of lidocaine for the treatment of chronic neuropathic pain and post-surgical pain. A phase I study has been completed in chronic scrotal pain and a phase II study in post-operative pain has been initiated.

Total Flow Medical



Total Flow Medical's mission is to improve the length and quality of life for heart surgery and life support patients. Their first product is a cannula for cardiopulmonary bypass, used during minimally invasive heart surgery. Costing the US healthcare system an estimate \$1B per year, standard cannula can block blood flow in patients' legs- leading to ischemic limb conditions, amputation and even death. With their patented solution, they plan to become the standard of care in femoral cannulation and start by treating the 100k US patients per year.

Variational AI



VARIATIONAL AI

Variational AI is a drug discovery platform startup that generates novel, potent, selective, and synthesizable compounds for validated targets across disease areas. They generate optimized leads in months and license to biopharmas. We are active in oncology, infectious disease, and CNS.

Vesalius Cardiovascular



Vesalius is developing a Transfemoral Mitral Valve repair (TMVr) solution for Degenerative Mitral Regurgitation (DMR) patients. They are currently at preclinical stage and planning an Early Feasibility Study (IDE) in 2022. They successfully embedded current proven surgical techniques in an engineered device that is delivered to the heart through a skin puncture to the femoral vein. Based upon chordal replacement and annuloplasty, their solution is a comprehensive Mitral Valve repair in textbook fashion, disease complexity-agnostic, using a standardized procedure and a 1 size fits all device for all DMR patients. It is basically heart surgery, but with a catheter.



VoxCell BioInnovation



VoxCell BioInnovation

VoxCell is creating an extraordinary line of Truly Biomimetic solutions for the drug development industry and the field of Oncology research. Their line of proprietary solutions enables drug developers and researchers to have the tools for increased translatable pre-clinical results before therapies are tested in humans. VoxCell's products (3D Bioprinter + Vascularization Software, Tissue Models, and Bioinks) provide a way to elevate in vitro testing. Their incredible software allows the user to create physiologically relevant vasculature within 3D bioprinted tissues, allowing for perfusion within a 3D environment, a step above traditional methods of testing on cell monolayers and spheroids. Whether it is pharmaceutical companies testing new drugs in the lab, or medical professionals determining which therapy is best for their patient, VoxCell is changing the way people think about in vitro tissue models through 3D bioprinting.



XCO Tech Inc.



XCO is dedicated to advancing physical and cognitive performance across the spectrum of health and aging. Founded in 2014 and headquartered in Penticton, BC, the company has developed a portfolio of proprietary technologies to assess movement and cognition in athletes and patients. Building on that portfolio, XCO is now launching a novel AI-based biometrics health patch, called the Virtual Care Patch, designed to empower patients and healthcare practitioners with real-time predictive health analytics, supporting the rapid transition to virtualized care.



YouCount Inc.




YouCount is a health-tech company developing next generation, at-home medical devices for biomarker measurement. YouCount's lead product is HealthCheck, a cloud-connected, at-home IVD medical device which measures 8-to-12 key biomarkers in urine. Urine tests are non-invasive and done by patients at-home. HealthCheck has remote monitoring capability for doctors/clinicians to monitor test results of patients. They believe at-home and point-of-care biomarker testing will become a predominate part of healthcare in the next 5 years. Human urine holds an incredible amount of biomarker information (24+ analytes) and YouCount is positioning to be a leader in this field.



Zennea Technologies Inc.



Zennea Technologies is a medical device company, ending sleepless nights for adults with mild obstructive sleep apnea (OSA) and chronic snoring using their wearable system. The ZENS System addresses the underlying physiological cause of the conditions while keeping the physician engaged in the treatment process. Zennea's team of experienced clinical and medical device professionals are working to make their technology the gold standard of care for the 1 in 10 adults in the US that suffer from the conditions.



For more information on membership or sponsorship opportunities please contact:

Ryan Butt

Director, Partnerships & Event
rbutt@lifesciencesbc.ca

Peter McLoughlin

Manager, Partnerships & Membership
pmcloughlin@lifesciencesbc.ca

PRESENTING SPONSOR



CONFERENCE PARTNER



SESSION SPONSORS



NETWORKING & TECHNOLOGY SPONSORS

EVENT SUPPORTERS

